196 related articles for article (PubMed ID: 32757711)
1. Tumour necrosis factor inhibitor-induced myositis in a patient with ulcerative colitis.
Yoshida A; Katsumata Y; Hirahara S; Hanaoka M; Ochiai M; Kobayashi M; Harigai M
Mod Rheumatol Case Rep; 2021 Jan; 5(1):156-161. PubMed ID: 32757711
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. [Case of eosinophilic myositis in continuum from localized nodular myositis].
Matsuse D; Ikezoe K; Shigeto H; Murai H; Ohyagi Y; Kira J
Rinsho Shinkeigaku; 2008 Jan; 48(1):36-42. PubMed ID: 18386630
[TBL] [Abstract][Full Text] [Related]
4. [Non-granulomatous myositis in a patient with ulcerative colitis who showed symptoms resembling gastrocnemius myalgia syndrome].
Yamamoto M; Inoue M; Tachibana N; Tsuzaki K; Shibata Y; Hamano T
Rinsho Shinkeigaku; 2017 Feb; 57(2):71-76. PubMed ID: 28132973
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report.
Alhalabi M; Eddin KA; Ali F; Abbas A
Medicine (Baltimore); 2022 Jan; 101(4):e28722. PubMed ID: 35089243
[TBL] [Abstract][Full Text] [Related]
6. Recovery from hypoxemia and Hypercapnia following noninvasive pressure support ventilation in a patient with statin-associated necrotizing myopathy: a case report.
Yamamura Y; Matsumoto Y; Tadokoro K; Ohta Y; Sato K; Yamashita T; Yamamura M; Sada KE; Abe K; Wada J
BMC Pulm Med; 2020 Jun; 20(1):156. PubMed ID: 32493279
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
Kobayashi T; Motoya S; Nakamura S; Yamamoto T; Nagahori M; Tanaka S; Hisamatsu T; Hirai F; Nakase H; Watanabe K; Matsumoto T; Tanaka M; Abe T; Suzuki Y; Watanabe M; Hibi T;
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):429-437. PubMed ID: 33887262
[TBL] [Abstract][Full Text] [Related]
8. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
9. Irreversible optic neuritis after infliximab treatment in a patient with ulcerative colitis.
Clemmensen K; Akrawi N; Stawowy M
Scand J Gastroenterol; 2015; 50(12):1508-11. PubMed ID: 26133362
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
Panaccione R; Ghosh S; Middleton S; Márquez JR; Scott BB; Flint L; van Hoogstraten HJ; Chen AC; Zheng H; Danese S; Rutgeerts P
Gastroenterology; 2014 Feb; 146(2):392-400.e3. PubMed ID: 24512909
[TBL] [Abstract][Full Text] [Related]
12. C1-inhibitor Deficiency Induces Myositis-like Symptoms Via the Deposition of the Membrane Attack Complex in the Muscle.
Beck G; Yamashita R; Saeki C; Ogawa T; Shimizu M; Mochizuki H
Intern Med; 2020 Sep; 59(17):2173-2176. PubMed ID: 32461528
[TBL] [Abstract][Full Text] [Related]
13. Evolution of Seronegative Inflammatory Myositis to Dermatomyositis With Characteristic Cutaneous Features: A Case Report.
Jevtic D; Dharmah U; Bahar M
J Investig Med High Impact Case Rep; 2023; 11():23247096231217829. PubMed ID: 38097369
[TBL] [Abstract][Full Text] [Related]
14. A case of granulomatous myositis in a patient with rheumatoid arthritis receiving anti-TNF-α treatment.
Kawamura A; Tsuchida Y; Shoda H; Kubo K; Uchio N; Shimizu J; Fujio K
Mod Rheumatol Case Rep; 2020 Jan; 4(1):1-5. PubMed ID: 33086966
[TBL] [Abstract][Full Text] [Related]
15. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced paraspinal myositis mimicking acute bilateral sciatica.
Pearse R; Visagan R; Reddy K; Dev S
BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30796068
[TBL] [Abstract][Full Text] [Related]
18. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
Berends SE; van Steeg TJ; Ahsman MJ; Singh S; Brandse JF; D'Haens GRAM; Mathôt RAA
J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):543-551. PubMed ID: 31489538
[TBL] [Abstract][Full Text] [Related]
20. Anti-U3 ribonucleoprotein antibody-positive inflammatory myopathy: a case report.
Murata KY; Nakatani K; Yananeki M; Nakanishi I; Ito H
J Med Case Rep; 2016 Jun; 10():169. PubMed ID: 27283724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
